Peptides · Research only

Peptide dosage protocols — what communities report

Research and education only — not medical advice. Everything below describes what online peptide communities report doing. It is not a protocol to follow, not a dosing recommendation, and not an endorsement.

There are no published human studies establishing any dose, schedule, or safety profile for these blends. These compounds are not approved medicines; most are sold explicitly for laboratory research and are not for human consumption. Quality, purity and contents of grey-market vials are unverified. Any decision about your health belongs with a qualified clinician.

Wolverine stack

Community-reported — no human studies

Contains: BPC-157 + TB-500 (usually co-freeze-dried in one vial)

What the community reports doing

Named by user communities after the comic character's healing — the name is marketing folklore, not science.
Community discussions describe running it in time-limited blocks (often described as a few weeks on, then a break) rather than continuously.
Users commonly describe injecting near — not necessarily into — the area of concern, and rotating sites.
Log-book style tracking of dose, site, and symptoms is common in communities, because there is no published regimen to follow.

What the evidence actually shows

BPC-157's human evidence is essentially limited to small, low-quality reports; TB-500 (thymosin beta-4 fragment) has early human data for unrelated indications. Neither has an established human dose for musculoskeletal repair, and the combination itself has never been studied.

Community protocol booklet — as reported

Wolverine-style BPC-157 + TB-500 + KPV · 10 + 10 + 10 mg (30 mg combo vial)

Mixing math: 30 mg + 3.0 mL bacteriostatic water = 10 mg/mL total (≈3.33 mg/mL of each). Refrigerate 2–8 °C; booklet says use within 28 days.

Weeks 1–4

Load

10 units daily (7×/week)

Weeks 5–8

Step-down

10 units, 5×/week (Mon–Fri)

Weeks 9–12

Maintain

10 units, 2–3×/week, then 4 weeks off

Units (U-100)	mL	Blend	Per component
5	0.05	0.50 mg	≈167 mcg each
10	0.10	1.00 mg	≈333 mcg each
15	0.15	1.50 mg	≈500 mcg each

Locked 1:1:1 ratio — components cannot be adjusted independently.
Booklet cycle: 8–12 weeks on, 4 weeks off (or 6 on / 6 off); subcutaneous, rotating sites.
Booklet advises not combining this vial with KLOW on the same day.

Source: a community research-reference booklet, which itself states these ranges are "community convention only" with no FDA-approved human dose. Shown for education — not a recommendation to use.

Every reported 'protocol' for this blend traces back to forum posts and vendor marketing, not trials. Anecdotes cannot establish that it works, that any schedule is right, or that it is safe — especially long term.

GLOW stack

Community-reported — no human studies

Contains: BPC-157 + TB-500 + GHK-Cu

What the community reports doing

Marketed in communities toward skin, collagen and wound appearance on top of the 'repair' rationale of the base pair.
Community discussions often note the blue tint of a reconstituted blend — that colour is the GHK-Cu copper complex, not a sign of potency or purity.
Reported schedules again follow time-limited blocks rather than continuous use, copied from Wolverine-stack folklore.

What the evidence actually shows

GHK-Cu has small human studies, largely topical and cosmetic. Injected GHK-Cu in a multi-peptide blend has no human trials. Adding a third compound multiplies unknowns — interactions between components have never been examined.

Community protocol booklet — as reported

GLOW · TB-500 10 + BPC-157 10 + GHK-Cu 50 mg (70 mg vial)

Mixing math: 70 mg + 3.0 mL bacteriostatic water = 23.33 mg/mL total blend. Refrigerate 2–8 °C; booklet says use within 28 days.

Weeks 1–4

Load

10 units daily (7×/week)

Weeks 5–8

Step-down

10 units, 5×/week (Mon–Fri)

Weeks 9–12

Maintain

10 units, 2–3×/week, then 4 weeks off

Units (U-100)	mL	Blend	Per component
5	0.05	1.17 mg	GHK-Cu 0.83 mg · BPC/TB ≈167 mcg
10	0.10	2.33 mg	GHK-Cu 1.67 mg · BPC/TB ≈330 mcg
12	0.12	2.80 mg	GHK-Cu 2.00 mg · BPC/TB ≈400 mcg

Booklet mentions a 3-day 5-unit start because GHK-Cu injection sting is common.
Booklet cycle: 8–12 weeks on, 4 weeks off (cited reason: copper load).

Source: a community research-reference booklet, which itself states these ranges are "community convention only" with no FDA-approved human dose. Shown for education — not a recommendation to use.

Skin-quality anecdotes are among the least reliable evidence that exists: lighting, weight change and expectation all move appearance. No controlled trial has tested GLOW as a fixed combination.

KLOW stack

Community-reported — no human studies

Contains: KPV + BPC-157 + TB-500 + GHK-Cu

What the community reports doing

The broadest community blend — GLOW plus KPV, an alpha-MSH fragment studied in lab models of gut and skin inflammation.
Communities position it toward gut and inflammatory concerns, again in self-managed blocks copied from the other stacks.
Vendors sell all four co-mixed in one vial; communities debate separate versus combined vials with no data to settle it.

What the evidence actually shows

KPV's evidence is preclinical — cell and animal models of inflammation. The four-way combination has never been studied in any model as a fixed product, let alone in humans.

Community protocol booklet — as reported

KLOW · TB-500 10 + BPC-157 10 + GHK-Cu 50 + KPV 10 mg (80 mg vial)

Mixing math: 80 mg + 3.0 mL bacteriostatic water = 26.67 mg/mL total blend. Refrigerate 2–8 °C; booklet says use within 28 days.

Weeks 1–4

Load

10 units daily (7×/week)

Weeks 5–8

Step-down

10 units, 5×/week (Mon–Fri)

Weeks 9–12

Maintain

10 units, 2–3×/week, then 4 weeks off

Units (U-100)	mL	Blend	Per component
5	0.05	1.33 mg	GHK-Cu 0.83 mg · BPC/TB/KPV ≈167 mcg
10	0.10	2.67 mg	GHK-Cu 1.67 mg · BPC/TB/KPV ≈333 mcg
12	0.12	3.20 mg	GHK-Cu 2.00 mg · BPC/TB/KPV ≈400 mcg

Booklet cycle: 8–12 weeks on, 4 weeks off, or an alternate 6 on / 6 off.
All four components sit in one draw — none can be adjusted on its own.

Source: a community research-reference booklet, which itself states these ranges are "community convention only" with no FDA-approved human dose. Shown for education — not a recommendation to use.

Stacking four unstudied compounds does not add their rationales together — it multiplies unknowns. There is no evidence base for any KLOW schedule, dose or duration, and no way to attribute benefits or side effects to one component.

Download · Research only

Peptide Dosage Protocols PDF

Every community blend and booklet card in one printable file, with disclaimers and our preferred vetted supplier listed at the bottom.

Community protocol booklet — all compounds

Research and education only — not medical advice. These cards reproduce a community research-reference booklet as reported. Mixing math is simple arithmetic; approved-drug steps (tirzepatide, semaglutide) mirror FDA labels; retatrutide, eloralintide and cagrilintide follow published trial schedules and are not FDA-approved; everything else is community convention with no established human dose. Tap a card to expand it. Talk to a qualified clinician before any health decision.

Cross-check results (September 2026)

Matches official labels: tirzepatide 2.5 → 15 mg and semaglutide 0.25 → 2.4 mg steps (every 4 weeks); tesamorelin 1.4–2 mg daily; thymosin alpha-1 1.6 mg twice weekly.
Close to published trials, with differences: retatrutide (trial used 2 → 4 → 8 → 12 mg, no 6 mg step) and eloralintide (1–9 mg weekly arms). Flagged on those cards.
Consistent with what vendors and communities widely repeat, but not studied in people: BPC-157 250–500 mcg, TB-500 2–2.5 mg twice weekly, GHK-Cu 1–2 mg, and blend makeups such as KLOW 50/10/10/10 mg and GLOW 50/10/10 mg. "Found everywhere" means often repeated, not proven.
Mixing math: spot-checked, and the numbers add up for the vial sizes shown.

RetatrutideTriple agonist research analog · 10 mg vial

10 mg vial · 5 mg/mL · SubQ weekly

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 20 units = 1.0 mg. 40 units = 2.0 mg. 80 units = 4.0 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 10 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–12 · WEEK 13+

Start · Step · Step · Hold / step

1–2 mg · 4 mg · 6–8 mg · 8–12 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

Assess tolerance · Hold if GI sides · Research range · Do not rush

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Doses / vial · Fits this vial?

1 mg · 20 · 0.20 · 10 · Yes — start vial

2 mg · 40 · 0.40 · 5 · Yes

4 mg · 80 · 0.80 · 2.5 · Tight — prefer 20 mg

6 mg · 120 · 1.20 · 1.6 · Move to 20 / 30 mg

8–12 mg · 160–240 · 1.60–2.40 · — · Use 20 / 30 mg vial

This 10 mg vial is the start-step vial (1–2 mg). Switch to the 20 mg or 30 mg card once the weekly dose is 4 mg or higher.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly, same weekday.

• Duration: research blocks are commonly 12–24 weeks with a hold at the last tolerated step.

• Do not double a missed weekly dose. GI effects drive the pace — stay at a step 4 extra weeks if needed.

• Sister cards: 20 mg vial (10 mg/mL) and 30 mg vial (10 mg/mL).

FACT-CHECK: The NEJM 2023 Phase 2 trial escalated every 4 weeks through 2 → 4 → 8 → 12 mg (final arms 1, 4, 8, 12 mg). It had no 6 mg step — the booklet's "6–8 mg" range is a community adaptation, not the trial schedule.

Community-reported reference — not a recommendation to use.

RetatrutideTriple agonist research analog · 20 mg vial

20 mg vial · 10 mg/mL · SubQ weekly

RECONSTITUTION

20 mg + 2.0 mL bac water = 10 mg/mL.

U-100: 10 units = 1.0 mg. 40 units = 4.0 mg. 80 units = 8.0 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 20 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–12 · WEEK 13+

Start · Step · Step · Hold / step

1–2 mg · 4 mg · 6–8 mg · 8–12 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

Assess tolerance · Hold if GI sides · Research range · Do not rush

DRAW TABLE · 20 mg IN 2.0 mL (10 mg/mL)

Dose · Units · mL · Doses / vial

1 mg · 10 · 0.10 · 20

2 mg · 20 · 0.20 · 10

4 mg · 40 · 0.40 · 5

6 mg · 60 · 0.60 · ~3

8 mg · 80 · 0.80 · 2.5

12 mg · 120 · 1.20 · 1.6

Titrate no faster than every 4 weeks. 12 mg is 120 units — split across two syringes or accept a 1.20 mL draw.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly, same weekday.

• Duration: research blocks are commonly 12–24 weeks with a hold at the last tolerated step.

• Do not double a missed weekly dose. GI effects drive the pace — stay at a step 4 extra weeks if needed.

• Sister cards: 10 mg vial for the 1–2 mg start; 30 mg vial when you want more doses at 8–12 mg.

Community-reported reference — not a recommendation to use.

RetatrutideTriple agonist research analog · 30 mg vial

30 mg vial · 10 mg/mL · SubQ weekly

RECONSTITUTION

30 mg + 3.0 mL bac water = 10 mg/mL.

U-100: 10 units = 1.0 mg. 40 units = 4.0 mg. 80 units = 8.0 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 30 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–12 · WEEK 13+

Start · Step · Step · Hold / step

1–2 mg · 4 mg · 6–8 mg · 8–12 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

Assess tolerance · Hold if GI sides · Research range · Do not rush

DRAW TABLE · 30 mg IN 3.0 mL (10 mg/mL)

Dose · Units · mL · Doses / vial

2 mg · 20 · 0.20 · 15

4 mg · 40 · 0.40 · 7.5

6 mg · 60 · 0.60 · 5

8 mg · 80 · 0.80 · 3.75

12 mg · 120 · 1.20 · 2.5

Same 10 mg/mL math as the 20 mg card — this vial simply lasts longer at the 6–12 mg steps.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly, same weekday.

• Duration: research blocks are commonly 12–24 weeks with a hold at the last tolerated step.

• Do not double a missed weekly dose. GI effects drive the pace — stay at a step 4 extra weeks if needed.

• Sister cards: 10 mg and 20 mg. Pick the vial that covers the current step without multi-draw waste.

Community-reported reference — not a recommendation to use.

TirzepatideDual GIP / GLP-1 research analog · 10 mg vial

10 mg vial · 5 mg/mL · SubQ weekly

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 50 units = 2.5 mg. 100 units = 5.0 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 10 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–12 · WEEK 13+

Start · Step · Step · Hold / step

2.5 mg · 5 mg · 7.5–10 mg · 12.5–15 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

Tolerance · Ceiling

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Doses / vial · Fits this vial?

2.5 mg · 50 · 0.50 · 4 · Yes — start vial

5 mg · 100 · 1.00 · 2 · Tight — prefer 20 mg

7.5 mg · 150 · 1.50 · 1.3 · Move to 20 / 30 mg

10 mg · 200 · 2.00 · 1 · Whole vial / one week

12.5–15 mg · 250–300 · 2.50–3.00 · — · Use 20 / 30 mg vial

Step every 4 weeks only. Hold longer if nausea, constipation, or appetite drop is excessive. This 10 mg vial is the 2.5 mg start vial.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly.

• Duration: research blocks commonly 16–24+ weeks. Stay at the last comfortable step.

• Missed dose: if <4 days late, take it; if later, skip and resume the usual day.

• Sister cards: 20 mg and 30 mg vials at 10 mg/mL. Move up once weekly dose exceeds 5 mg.

Community-reported reference — not a recommendation to use.

TirzepatideDual GIP / GLP-1 research analog · 20 mg vial

20 mg vial · 10 mg/mL · SubQ weekly

RECONSTITUTION

20 mg + 2.0 mL bac water = 10 mg/mL.

U-100: 25 units = 2.5 mg. 50 units = 5.0 mg. 100 units = 10 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 20 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–12 · WEEK 13+

Start · Step · Step · Hold / step

2.5 mg · 5 mg · 7.5–10 mg · 12.5–15 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

Tolerance · Ceiling

DRAW TABLE · 20 mg IN 2.0 mL (10 mg/mL)

Dose · Units · mL · Doses / vial

2.5 mg · 25 · 0.25 · 8

5 mg · 50 · 0.50 · 4

7.5 mg · 75 · 0.75 · ~2.5

10 mg · 100 · 1.00 · 2

12.5 mg · 125 · 1.25 · 1.6

15 mg · 150 · 1.50 · 1.3

Step every 4 weeks only. 15 mg is 150 units — one and a half U-100 syringes, or accept a 1.50 mL draw.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly.

• Duration: research blocks commonly 16–24+ weeks. Stay at the last comfortable step.

• Missed dose: if <4 days late, take it; if later, skip and resume the usual day.

• Sister cards: 10 mg start vial; 30 mg vial when holding 10–15 mg weekly.

Community-reported reference — not a recommendation to use.

TirzepatideDual GIP / GLP-1 research analog · 30 mg vial

30 mg vial · 10 mg/mL · SubQ weekly

RECONSTITUTION

30 mg + 3.0 mL bac water = 10 mg/mL.

U-100: 25 units = 2.5 mg. 50 units = 5.0 mg. 100 units = 10 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 30 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–12 · WEEK 13+

Start · Step · Step · Hold / step

2.5 mg · 5 mg · 7.5–10 mg · 12.5–15 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

Tolerance · Ceiling

DRAW TABLE · 30 mg IN 3.0 mL (10 mg/mL)

Dose · Units · mL · Doses / vial

5 mg · 50 · 0.50 · 6

7.5 mg · 75 · 0.75 · 4

10 mg · 100 · 1.00 · 3

12.5 mg · 125 · 1.25 · 2.4

15 mg · 150 · 1.50 · 2

Same 10 mg/mL math as the 20 mg card — this vial covers two full 15 mg weekly doses.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly.

• Duration: research blocks commonly 16–24+ weeks. Stay at the last comfortable step.

• Missed dose: if <4 days late, take it; if later, skip and resume the usual day.

• Sister cards: 10 mg and 20 mg. Prefer this vial once weekly dose is 10 mg or higher.

Community-reported reference — not a recommendation to use.

SemaglutideGLP-1 research analog · 10 mg vial

10 mg vial · 5 mg/mL · SubQ weekly

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 5 units = 0.25 mg. 10 units = 0.50 mg. 48 units = 2.4 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 10 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–16 · WEEK 17+

Start · Step · Step · Hold

0.25 mg · 0.50 mg · 1.0–1.7 mg · 1.7–2.4 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

GI watch · Hold if needed · Label ladder · Ceiling

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Doses / vial

0.25 mg · 5 · 0.05 · 40

0.50 mg · 10 · 0.10 · 20

1.0 mg · 20 · 0.20 · 10

1.7 mg · 34 · 0.34 · ~6

2.4 mg · 48 · 0.48 · ~4

Titration 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg every 4 weeks follows the labeled Wegovy schedule. Hold any step longer if GI sides are excessive.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly, same weekday.

• Duration: research blocks commonly 16–68+ weeks. Stay at the last comfortable step.

• Do not double a missed weekly dose. If <5 days late, take it; if later, skip and resume the usual day.

• Sister card: 20 mg vial. This 10 mg vial covers a full start-to-2.4 mg titration (~4 weeks at ceiling).

Community-reported reference — not a recommendation to use.

SemaglutideGLP-1 research analog · 20 mg vial

20 mg vial · 10 mg/mL · SubQ weekly

RECONSTITUTION

20 mg + 2.0 mL bac water = 10 mg/mL.

U-100: 2.5 units = 0.25 mg. 10 units = 1.0 mg. 24 units = 2.4 mg.

Optional easier-start recon: 20 mg + 4.0 mL = 5 mg/mL (then use the 10 mg card’s unit table).

WEEKLY TITRATION · THIS 20 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–16 · WEEK 17+

Start · Step · Step · Hold

0.25 mg · 0.50 mg · 1.0–1.7 mg · 1.7–2.4 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

GI watch · Hold if needed · Label ladder · Ceiling

DRAW TABLE · 20 mg IN 2.0 mL (10 mg/mL)

Dose · Units · mL · Doses / vial

0.25 mg · 2.5 · 0.025 · 80

0.50 mg · 5 · 0.05 · 40

1.0 mg · 10 · 0.10 · 20

1.7 mg · 17 · 0.17 · ~12

2.4 mg · 24 · 0.24 · ~8

Starter 0.25 mg is a 2.5-unit micro-draw. Use a 0.3 mL syringe, or recon this vial with 4.0 mL so 0.25 mg = 5 units.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly, same weekday.

• Duration: research blocks commonly 16–68+ weeks. Stay at the last comfortable step.

• Do not double a missed weekly dose. If <5 days late, take it; if later, skip and resume the usual day.

• Sister card: 10 mg vial. Prefer this 20 mg vial once weekly dose is 1.7–2.4 mg.

Community-reported reference — not a recommendation to use.

CagrilintideLong-acting amylin analog · 10 mg vial

10 mg vial · 5 mg/mL · SubQ weekly

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 6 units = 0.30 mg. 12 units = 0.60 mg. 24 units = 1.20 mg. 48 units = 2.40 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS COMPOUND

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–12

Start · Step · Step

0.3–0.6 mg · 1.2 mg · 1.8–2.4 mg

1× weekly · 1× weekly · 1× weekly

GI watch · Common hold

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Doses / vial

0.30 mg · 6 · 0.06 · ~33

0.60 mg · 12 · 0.12 · ~16

1.20 mg · 24 · 0.24 · ~8

2.40 mg · 48 · 0.48 · ~4

Often researched alongside a GLP analog on a different injection day. Do not stack same-day high GLP + high cagrilintide when starting.

DURATION · ROUTE · NOTES

• Route: subcutaneous, once weekly.

• Duration: 12–24 week research blocks. Nausea is the limiter — extend any step to 8 weeks if needed.

• One 10 mg vial covers a full start-to-1.2 mg titration with remainder for a hold phase.

Community-reported reference — not a recommendation to use.

Cagrilintide + Semaglutide1:1 amylin + GLP-1 blend · 5 mg + 5 mg · 10 mg combo vial

5 + 5 mg vial · 2.5 mg/mL each · SubQ weekly

RECONSTITUTION

10 mg combo (5 mg cagrilintide + 5 mg semaglutide) + 2.0 mL bac water = 5 mg/mL total (2.5 mg/mL each).

U-100: 10 units = 0.25 mg each. 20 units = 0.50 mg each. 40 units = 1.0 mg each.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 1:1 BLEND

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–16 · WEEK 17+

Start · Step · Step · Hold

0.25 / 0.25 mg · 0.50 / 0.50 mg · 1.0 / 1.7 mg · 1.7–2.4 mg ea.

1× weekly · 1× weekly · 1× weekly · 1× weekly

GI watch · Hold if needed · Each component · REDEFINE range

DRAW TABLE · 10 mg COMBO IN 2.0 mL (2.5 mg/mL each)

Each component · Units · mL · Cagri · Sema · Doses / vial

0.25 mg · 10 · 0.10 · 0.25 mg · 0.25 mg · 20

0.50 mg · 20 · 0.20 · 0.50 mg · 0.50 mg · 10

1.00 mg · 40 · 0.40 · 1.00 mg · 1.00 mg · 5

1.70 mg · 68 · 0.68 · 1.70 mg · 1.70 mg · ~3

2.40 mg · 96 · 0.96 · 2.40 mg · 2.40 mg · 2

Locked 1:1. CagriSema trial maintenance was 2.4 / 2.4 mg weekly. Separate vials are required for unequal dosing.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly.

• Duration: research blocks commonly 16–68 weeks. Combined GI burden can exceed either compound alone — extend steps.

• Do not add a second standalone semaglutide or cagrilintide pin on the same day as this blend.

• One 10 mg combo vial covers a full start-to-1.0 mg titration with remainder for a short hold.

Community-reported reference — not a recommendation to use.

EloralintideSelective AMY1R amylin analog (LY3841136) · 20 mg vial

20 mg vial · 10 mg/mL · SubQ weekly

RECONSTITUTION

20 mg + 2.0 mL bac water = 10 mg/mL.

U-100: 10 units = 1.0 mg. 30 units = 3.0 mg. 90 units = 9.0 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 20 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–12 · WEEK 13+

Start · Step · Step · Hold / step

1 mg · 3 mg · 6 mg · 6–9 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

Lowest fixed arm · Hold if GI / fatigue · Mid research range · Do not rush

DRAW TABLE · 20 mg IN 2.0 mL (10 mg/mL)

Dose · Units · mL · Doses / vial

1 mg · 10 · 0.10 · 20

3 mg · 30 · 0.30 · ~6

6 mg · 60 · 0.60 · ~3

9 mg · 90 · 0.90 · ~2

Phase 2 (Lancet 2025) used 1 / 3 / 6 / 9 mg once weekly. Not FDA-approved. This 20 mg vial is tight at 9 mg (~2 weekly doses).

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly, same weekday.

• Duration: published research blocks ran 12–48 weeks with a hold at the last tolerated step.

• Nausea and fatigue were dose-dependent in Phase 2. Extend any step 4 extra weeks rather than jumping.

• Do not stack same-day high GLP + high eloralintide when starting.

• Sister card: 50 mg vial when holding 6–9 mg weekly.

FACT-CHECK: Phase 2 tested once-weekly doses from 1 mg up to 9 mg, with dose escalation for the higher arms. The booklet's week-by-week timing is a community adaptation of those arms.

Community-reported reference — not a recommendation to use.

EloralintideSelective AMY1R amylin analog (LY3841136) · 50 mg vial

50 mg vial · 10 mg/mL · SubQ weekly

RECONSTITUTION

50 mg + 5.0 mL bac water = 10 mg/mL.

U-100: 10 units = 1.0 mg. 30 units = 3.0 mg. 90 units = 9.0 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

WEEKLY TITRATION · THIS 50 mg VIAL

WEEKS 1–4 · WEEKS 5–8 · WEEKS 9–12 · WEEK 13+

Start · Step · Step · Hold / step

1 mg · 3 mg · 6 mg · 6–9 mg

1× weekly · 1× weekly · 1× weekly · 1× weekly

Lowest fixed arm · Hold if GI / fatigue · Mid research range · Do not rush

DRAW TABLE · 50 mg IN 5.0 mL (10 mg/mL)

Dose · Units · mL · Doses / vial

1 mg · 10 · 0.10 · 50

3 mg · 30 · 0.30 · ~16

6 mg · 60 · 0.60 · ~8

9 mg · 90 · 0.90 · ~5

Same 10 mg/mL unit math as the 20 mg card — this vial lasts ~5 weeks at the 9 mg hold.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, once weekly, same weekday.

• Duration: published research blocks ran 12–48 weeks with a hold at the last tolerated step.

• Nausea and fatigue were dose-dependent in Phase 2. Extend any step 4 extra weeks rather than jumping.

• Do not stack same-day high GLP + high eloralintide when starting.

• Sister card: 20 mg vial for the 1–3 mg start steps.

FACT-CHECK: Phase 2 tested once-weekly doses from 1 mg up to 9 mg, with dose escalation for the higher arms. The booklet's week-by-week timing is a community adaptation of those arms.

Community-reported reference — not a recommendation to use.

TesamorelinGHRH analog · 10 mg vial

10 mg vial · 5 mg/mL · Nightly 5×/wk

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 20 units = 1.0 mg. 40 units = 2.0 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

WEEKS 1–8 · WEEKS 9–12

Standard · Optional

1 mg · 1–2 mg

Nightly, 5×/wk · Nightly, 5×/wk

Empty stomach · Then 4 wks off

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Vial life @ 5×/wk

1 mg · 20 · 0.20 · 2 weeks

2 mg · 40 · 0.40 · 1 week

An 8-week 1 mg × 5 days/week block uses 4 vials.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen. Last meal ≥90 minutes prior.

• Cycle: 8–12 weeks on, 4 weeks off. Often paired with Ipamorelin at a separate bedtime pin.

• Water retention and carpal tightness are the usual reasons to hold at 1 mg.

Community-reported reference — not a recommendation to use.

CJC-1295 (no DAC) + Ipamorelin5 mg + 5 mg blend · 10 mg combo vial

5 + 5 mg vial · Bedtime · 5 on / 2 off

RECONSTITUTION

10 mg combo (5 mg CJC no DAC + 5 mg Ipamorelin) + 2.0 mL bac water = 5 mg/mL total (2.5 mg/mL each).

U-100: 10 units = 250 mcg total (125 mcg each). 20 units = 500 mcg total (250 mcg each).

Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS BLEND

WEEKS 1–2 · WEEKS 3–12

Start · Working

200–250 mcg ea. · 250–300 mcg ea.

Nightly 5×/wk · Nightly 5×/wk

10–20 units · 20–24 units

DRAW TABLE · 10 mg COMBO IN 2.0 mL

Draw · CJC no DAC · Ipamorelin · Total · Vial life @ 5×/wk

10 u (0.10 mL) · 125 mcg · 125 mcg · 250 mcg · ~8 weeks

20 u (0.20 mL) · 250 mcg · 250 mcg · 500 mcg · ~4 weeks

24 u (0.24 mL) · 300 mcg · 300 mcg · 600 mcg · ~3.3 weeks

Empty stomach at bedtime. No food 60–90 minutes either side. 5 nights on / 2 off.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, bedtime.

• Cycle: 8–12 weeks on, 4 weeks off.

• This locked 1:1 blend cannot change the CJC:Ipa ratio. Separate vials are required for unequal dosing.

Community-reported reference — not a recommendation to use.

Tesamorelin + Ipamorelin10 mg + 3 mg · 13 mg combo vial

10 + 3 mg vial · Nightly 5 on / 2 off · Empty stomach

RECONSTITUTION

13 mg combo (10 mg tesamorelin + 3 mg ipamorelin) + 2.0 mL bac water = 5 mg/mL tesamorelin + 1.5 mg/mL ipamorelin.

U-100: 20 units = 1.0 mg tesamorelin + 300 mcg ipamorelin.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS BLEND

WEEKS 1–8 · WEEKS 9–12

Standard · Optional

1 mg + 300 mcg · Same draw

Nightly, 5×/wk · Nightly, 5×/wk

20 units · Then 4 wks off

DRAW TABLE · 13 mg COMBO IN 2.0 mL

Draw · Tesamorelin · Ipamorelin · Vial life @ 5×/wk

10 u (0.10 mL) · 0.50 mg · 150 mcg · ~4 weeks

20 u (0.20 mL) · 1.00 mg · 300 mcg · 2 weeks

40 u (0.40 mL) · 2.00 mg · 600 mcg · 1 week

Locked 10:3 ratio. Empty stomach at bedtime. No food 60–90 minutes either side.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, bedtime.

• Cycle: 8–12 weeks on, 4 weeks off.

• An 8-week 1 mg tesamorelin × 5 days/week block uses 4 combo vials.

• This locked blend cannot change the Tesa:Ipa ratio. Water retention / carpal tightness are the usual reasons to stay at 20 units.

Community-reported reference — not a recommendation to use.

HCGHuman chorionic gonadotropin · 10,000 IU vial

10,000 IU vial · 1,000 IU/mL · 2–3× weekly

RECONSTITUTION

10,000 IU + 10.0 mL bac water = 1,000 IU/mL.

U-100: 25 units = 250 IU. 50 units = 500 IU. 100 units = 1,000 IU.

Refrigerate after mixing. Use within 30–60 days. Protect from light.

PROTOCOL · THIS VIAL

ANCILLARY · SHORT BLOCK

Low · Higher

250–500 IU · 1,000–2,000 IU

2–3× weekly · 2–3× weekly

Mon/Thu or M/W/F · Time-limited

DRAW TABLE · 10,000 IU IN 10.0 mL (1,000 IU/mL)

Dose · Units · mL · Doses / vial

250 IU · 25 · 0.25 · 40

500 IU · 50 · 0.50 · 20

1,000 IU · 100 · 1.00 · 10

Working ancillary plan: 500 IU twice weekly uses one vial in 10 weeks.

DURATION · ROUTE · NOTES

• Route: subcutaneous or intramuscular.

• Do not run high-IU blocks indefinitely. Match duration to the research question (weeks, not months at 1,000+ IU).

• Allow vial to reach room temp before drawing to reduce sting.

Community-reported reference — not a recommendation to use.

BPC-157Body protection compound-157 · 10 mg vial

10 mg vial · 5 mg/mL · 1–2× daily

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 5 units = 250 mcg. 10 units = 500 mcg.

Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

WEEKS 1–4 · WEEKS 5–8

Working · Continue / taper

250–500 mcg · 250–500 mcg

1–2× daily · Once daily

Near target or abdomen · Then 2–4 wks off

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Vial life @ 500 mcg/day

250 mcg · 5 · 0.05 · 40 days (if once daily)

500 mcg · 10 · 0.10 · 20 days

500 mcg BID · 10 + 10 · 0.10 twice · 10 days

Local pin when the research target is a specific soft-tissue site; abdomen for systemic.

DURATION · ROUTE · NOTES

• Route: subcutaneous.

• Cycle: 4–8 weeks on, 2–4 weeks off. Short half-life is why once or twice daily is used.

• One 10 mg vial covers ~3 weeks at 500 mcg daily.

Community-reported reference — not a recommendation to use.

TB-500 (Thymosin 4 fragment)Actin-binding peptide fragment · 10 mg vial

10 mg vial · 5 mg/mL · 2× weekly load

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 40 units = 2.0 mg. 50 units = 2.5 mg.

Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

WEEKS 1–4 · WEEKS 5–8

Load · Maintain

2–2.5 mg · 2–2.5 mg

2× weekly · 1× weekly

Mon / Thu · Then 4 wks off

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Load-phase vial life

2.0 mg · 40 · 0.40 · 2.5 weeks @ 2×/wk

2.5 mg · 50 · 0.50 · 2 weeks @ 2×/wk

Daily micro-dosing is not the usual schedule for this fragment. Keep ≥72 hours between load doses.

DURATION · ROUTE · NOTES

• Route: subcutaneous (site is not critical — systemic).

• Cycle: 4–6 week load + 2–4 week weekly hold, then 4 weeks off.

• A 4-week 2.5 mg twice-weekly load uses two 10 mg vials.

Community-reported reference — not a recommendation to use.

BPC-157 + TB-50010 mg + 10 mg · 20 mg combo vial

10 + 10 mg vial · Locked 1:1 · 4–8 week blocks

RECONSTITUTION

20 mg combo + 2.0 mL bac water = 10 mg/mL total (5 mg/mL each).

U-100: 10 units = 500 mcg each. 40 units = 2.0 mg each.

Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS BLEND

OPTION A · OPTION B

Daily split · Hybrid

250–500 mcg each · BPC daily + TB 2×/wk

Daily · See notes

10 u = 500 mcg each · Needs extra TB math

DRAW TABLE · 20 mg COMBO IN 2.0 mL

Draw · BPC-157 · TB-500 · Use

5 u (0.05 mL) · 250 mcg · 250 mcg · Daily low

10 u (0.10 mL) · 500 mcg · 500 mcg · Daily working

40 u (0.40 mL) · 2.0 mg · 2.0 mg · Twice-weekly TB-style

Locked 1:1. Daily 10 units under-doses TB vs a classic 2 mg twice-weekly TB schedule. Add a standalone TB-500 vial if that schedule is the goal.

DURATION · ROUTE · NOTES

• Route: subcutaneous. Near-target for BPC-style work; abdomen otherwise.

• Cycle: 4–8 weeks on, 2–4 weeks off.

• One combo vial at 10 units daily lasts 20 days.

Community-reported reference — not a recommendation to use.

GHK-CuCopper tripeptide-1 · 100 mg vial

100 mg vial · 20 mg/mL · 5× weekly

RECONSTITUTION

100 mg + 5.0 mL bac water = 20 mg/mL.

U-100: 5 units = 1.0 mg. 10 units = 2.0 mg.

Blue solution is expected. Refrigerate 2–8 °C, dark. Use within 28 days.

PROTOCOL · THIS VIAL

WEEKS 1–8 · WEEKS 9–12

Working · Hold / taper

1–2 mg · 1 mg

5× / week · 3× / week

Mon–Fri · Then 4 wks off

DRAW TABLE · 100 mg IN 5.0 mL (20 mg/mL)

Dose · Units · mL · Vial life @ 5×/wk

1 mg · 5 · 0.05 · 20 weeks

1.67 mg · 8.5 · 0.085 · ~12 weeks

2 mg · 10 · 0.10 · 10 weeks

Sting is common. More water and a slow inject reduce it. Do not exceed short high-dose bursts without an off-window.

DURATION · ROUTE · NOTES

• Route: subcutaneous. Rotate sites.

• Cycle: 8–12 weeks on, 4 weeks off (copper).

• One 100 mg vial at 2 mg × 5 days/week lasts 10 weeks.

Community-reported reference — not a recommendation to use.

AHK-CuCopper tripeptide analog (Ala-His-Lys-Cu) · 100 mg vial

100 mg vial · 20 mg/mL · 5× weekly

RECONSTITUTION

100 mg + 5.0 mL bac water = 20 mg/mL.

U-100: 5 units = 1.0 mg. 10 units = 2.0 mg.

Blue-green solution is expected. Refrigerate 2–8 °C, dark. Use within 28 days.

PROTOCOL · THIS VIAL

WEEKS 1–8 · WEEKS 9–12

Working · Hold / taper

1–2 mg · 1 mg

5× / week · 3× / week

Mon–Fri · Then 4 wks off

DRAW TABLE · 100 mg IN 5.0 mL (20 mg/mL)

Dose · Units · mL · Vial life @ 5×/wk

0.50 mg · 2.5 · 0.025 · 40 weeks

1.00 mg · 5 · 0.05 · 20 weeks

2.00 mg · 10 · 0.10 · 10 weeks

Sting is common with copper peptides. A 0.3 mL syringe helps at 2.5–5 unit draws.

DURATION · ROUTE · NOTES

• Route: subcutaneous. Rotate sites.

• Cycle: 8–12 weeks on, 4 weeks off (copper load / receptor rest).

• One 100 mg vial at 2 mg × 5 days/week lasts 10 weeks.

• Do not stack a full GHK-Cu dose on the same days without counting total copper load.

Community-reported reference — not a recommendation to use.

KPVα-MSH fragment (Lys-Pro-Val) · 10 mg vial

10 mg vial · 5 mg/mL · Daily

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 4 units = 200 mcg. 10 units = 500 mcg.

Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

WEEKS 1–4 · WEEKS 5–8

Working · Continue

200–500 mcg · 200–500 mcg

Once daily · Once daily

Abdomen · Then 2–4 wks off

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Vial life @ daily

200 mcg · 4 · 0.04 · 50 days

250 mcg · 5 · 0.05 · 40 days

500 mcg · 10 · 0.10 · 20 days

If already running KLOW, KPV is included — do not stack a second full KPV dose from this vial on the same day.

DURATION · ROUTE · NOTES

• Route: subcutaneous (some research logs also use oral KPV; this flyer is for the injectable vial).

• Cycle: 4–8 weeks on, 2–4 weeks off.

Community-reported reference — not a recommendation to use.

AOD9604hGH fragment 176–191 · 10 mg vial

10 mg vial · 5 mg/mL · Daily fasted

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 5 units = 250 mcg. 10 units = 500 mcg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

WEEKS 1–4 · WEEKS 5–12

Working · Hold / optional step

250–300 mcg · 300–500 mcg

Once daily · Once daily

AM, fasted · Then 4 wks off

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Vial life @ daily

250 mcg · 5 · 0.05 · 40 days

300 mcg · 6 · 0.06 · ~33 days

500 mcg · 10 · 0.10 · 20 days

AOD9604 can gel if shaken or mixed cold. Warm the vial in the hand, swirl only.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen. Morning fasted is the usual research log.

• Cycle: 8–12 weeks on, 4 weeks off.

• One 10 mg vial at 300 mcg daily lasts about 4 weeks; discard at 28 days after recon.

• Community convention only. Published human work on this fragment was mostly oral / IV.

Community-reported reference — not a recommendation to use.

MOTS-CMitochondrial-derived peptide · 40 mg vial

40 mg vial · 20 mg/mL · 2–3× weekly

RECONSTITUTION

40 mg + 2.0 mL bac water = 20 mg/mL.

U-100: 25 units = 5 mg. 50 units = 10 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

WEEKS 1–4 · WEEKS 5–8

Load · Continue / taper

5–10 mg · 5–10 mg

2–3× weekly · 2× weekly

Mon/Thu or M/W/F · Then 4 weeks off

DRAW TABLE · 40 mg IN 2.0 mL (20 mg/mL)

Dose · Units · mL · Doses / vial

5 mg · 25 · 0.25 · 8

8 mg · 40 · 0.40 · 5

10 mg · 50 · 0.50 · 4

Working plan: 10 mg twice weekly × 4 weeks uses one 40 mg vial.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen or deltoid fat.

• Cycle: 4–8 weeks on, 4 weeks off. Do not run continuously.

• Timing: morning, training days preferred in research logs.

Community-reported reference — not a recommendation to use.

SS-31 (Elamipretide analog)Mitochondrial-targeted tetrapeptide · 50 mg vial

50 mg vial · 20 mg/mL · Daily or 5×/wk

RECONSTITUTION

50 mg + 2.5 mL bac water = 20 mg/mL.

U-100: 25 units = 5 mg. 50 units = 10 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

WEEKS 1–4 · WEEKS 5–8

Standard · Optional step

5 mg · 5–10 mg

Daily or 5×/wk · Daily or 5×/wk

AM · Then 2–4 wks off

DRAW TABLE · 50 mg IN 2.5 mL (20 mg/mL)

Dose · Units · mL · Vial life @ daily

5 mg · 25 · 0.25 · 10 days

10 mg · 50 · 0.50 · 5 days

A 4-week 5 mg × 5 days/week block uses ~100 mg (two vials).

DURATION · ROUTE · NOTES

• Route: subcutaneous.

• Cycle: 4–8 weeks on, 2–4 weeks off.

• Often logged in the same block as MOTS-C but on opposite weekdays to keep injection volume manageable.

Community-reported reference — not a recommendation to use.

NAD+Nicotinamide adenine dinucleotide · 500 mg vial

500 mg vial · 100 mg/mL · SubQ or IM

RECONSTITUTION

500 mg + 5.0 mL bac water = 100 mg/mL.

U-100: 50 units = 50 mg. 100 units = 100 mg. 200 units (two syringes) = 200 mg.

Protect from light. Refrigerate 2–8 °C. Use within 28 days. Solution may be pale yellow.

PROTOCOL · THIS 500 mg VIAL

WEEKS 1–2 · WEEKS 3–8

Start · Working

50–100 mg · 100–200 mg

2–3× weekly · 2–3× weekly

Flush-watch · SubQ or IM

DRAW TABLE · 500 mg IN 5.0 mL (100 mg/mL)

Dose · Units · mL · Doses / vial

50 mg · 50 · 0.50 · 10

100 mg · 100 · 1.00 · 5

200 mg · 200 · 2.00 · 2.5

Flushing and chest warmth can occur if pushed fast — inject slowly. Split large volumes across two sites.

DURATION · ROUTE · NOTES

• Route: subcutaneous or intramuscular. Slow inject.

• Cycle: 6–8 weeks on is a common research block; some run 100 mg twice weekly as maintenance.

• Do not mix NAD+ in the same syringe with other peptides.

• Sister card: 1000 mg vial, same 100 mg/mL math, twice the doses.

Community-reported reference — not a recommendation to use.

NAD+Nicotinamide adenine dinucleotide · 1000 mg vial

1000 mg vial · 100 mg/mL · SubQ or IM

RECONSTITUTION

1000 mg + 10.0 mL bac water = 100 mg/mL.

U-100: 50 units = 50 mg. 100 units = 100 mg. 200 units (two syringes) = 200 mg.

Protect from light. Refrigerate 2–8 °C. Use within 28 days. Solution may be pale yellow.

PROTOCOL · THIS 1000 mg VIAL

WEEKS 1–2 · WEEKS 3–8

Start · Working

50–100 mg · 100–200 mg

2–3× weekly · 2–3× weekly

Flush-watch · SubQ or IM

DRAW TABLE · 1000 mg IN 10.0 mL (100 mg/mL)

Dose · Units · mL · Doses / vial

50 mg · 50 · 0.50 · 20

100 mg · 100 · 1.00 · 10

200 mg · 200 · 2.00 · 5

Same 100 mg/mL unit math as the 500 mg card — this vial lasts twice as long. Split volumes over 1 mL across two sites.

DURATION · ROUTE · NOTES

• Route: subcutaneous or intramuscular. Slow inject.

• Cycle: 6–8 weeks on is a common research block; some run 100 mg twice weekly as maintenance.

• Do not mix NAD+ in the same syringe with other peptides.

• Sister card: 500 mg vial.

Community-reported reference — not a recommendation to use.

GlutathioneReduced L-glutathione · 1500 mg vial

1500 mg vial · 300 mg/mL · IM or slow SubQ

RECONSTITUTION

1500 mg + 5.0 mL bac water or sterile water = 300 mg/mL.

U-100: 33 units ≈ 100 mg. 67 units ≈ 200 mg. 100 units = 300 mg.

Use promptly after mixing. Refrigerate 2–8 °C, protect from light, use within 14–28 days.

PROTOCOL · THIS VIAL

WEEKS 1–8 · OPTIONAL

Working · Load week

200–400 mg · 400–600 mg

2–3× weekly · 3× weekly

IM preferred · Then step down

DRAW TABLE · 1500 mg IN 5.0 mL (300 mg/mL)

Dose · Units · mL · Doses / vial

200 mg · 67 · 0.67 · 7.5

300 mg · 100 · 1.00 · 5

500 mg · 167 · 1.67 · 3

Split volumes over 1 mL across two sites. IM deltoid or glute is the usual research route.

DURATION · ROUTE · NOTES

• Route: intramuscular preferred; slow subcutaneous if IM is not used.

• Cycle: 6–8 weeks on is a common block. Can sit as 200 mg twice weekly maintenance.

• Do not mix in the same syringe with NAD+ or peptides.

Community-reported reference — not a recommendation to use.

Vitamin B1210 mL multi-dose vial · confirm labeled mcg/mL on the lot

10 mL liquid · Read the lot · Weekly

RECONSTITUTION

This item ships as a 10 mL liquid vial — no reconstitution.

Read the printed concentration on the lot (commonly 1,000 mcg/mL or 5,000 mcg/mL).

Example if 1,000 mcg/mL: 100 units = 1.0 mL = 1,000 mcg.

PROTOCOL · THIS VIAL

STANDARD · LOADING

Weekly · Short

1,000 mcg · 1,000 mcg

1× weekly · 2–3× weekly × 2–4 wks

IM · Then weekly

EXAMPLE DRAWS · IF LABEL = 1,000 mcg/mL

Dose · Volume · Notes

500 mcg · 0.50 mL / 50 u · Low weekly

1,000 mcg · 1.00 mL / 100 u · Standard weekly IM

5,000 mcg · use 5,000 mcg/mL lot · Do not assume this concentration

Always dose from the printed mcg/mL. Do not apply this table to a 5,000 mcg/mL lot without dividing volume by 5.

DURATION · ROUTE · NOTES

• Route: intramuscular (deltoid) preferred; subcutaneous accepted.

• Protect from light. Refrigerate if the lot label requires it.

• Research-use framing only. Not a treatment plan.

Community-reported reference — not a recommendation to use.

EpitalonAEDG tetrapeptide bioregulator · 50 mg vial

50 mg vial · 10 mg/mL · Short course

RECONSTITUTION

50 mg + 5.0 mL bac water = 10 mg/mL.

U-100: 50 units = 5.0 mg. 100 units = 10.0 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

DAYS 1–20 · ALT. 10-DAY

Standard course · Shorter / higher

5 mg · 10 mg

Once daily · Once daily

Khavinson-style block · Then months off

DRAW TABLE · 50 mg IN 5.0 mL (10 mg/mL)

Dose · Units · mL · Vial life @ daily · Course math

5 mg · 50 · 0.50 · 10 days · Two vials / 20-day course

10 mg · 100 · 1.00 · 5 days · One vial / 5 days

Do not run continuously. Typical research cadence is a 10–20 day on-block, then 4–6 months off (1–2 courses per year).

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen. Evening is the usual log time.

• Cycle: 10–20 consecutive days on, then months off. This is not a weekly peptide.

• A 20-day 5 mg daily course uses two 50 mg vials.

• Community convention only — no FDA-approved human dose or standard vial IFU.

Community-reported reference — not a recommendation to use.

Thymosin Alpha-1Tα1 / thymalfasin analog · 5 mg vial

5 mg vial · 2.5 mg/mL · 2× weekly

RECONSTITUTION

5 mg + 2.0 mL bac water = 2.5 mg/mL.

U-100: 32 units ≈ 0.80 mg. 64 units = 1.60 mg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

STANDARD · LOWER

Zadaxin-neighborhood · If limited vial math

1.6 mg · 0.8–1.0 mg

2× weekly · 2× weekly

Mon / Thu · Then 4 wks off

DRAW TABLE · 5 mg IN 2.0 mL (2.5 mg/mL)

Dose · Units · mL · Doses / vial · Vial life @ 2×/wk

0.80 mg · 32 · 0.32 · ~6 · ~3 weeks

1.00 mg · 40 · 0.40 · 5 · 2.5 weeks

1.60 mg · 64 · 0.64 · ~3 · ~1.5 weeks

1.6 mg twice weekly is the long-standing thymalfasin (Zadaxin) schedule used in published trials outside the US. This card is a research analog flyer, not that

product IFU.

DURATION · ROUTE · NOTES

• Route: subcutaneous. Morning preferred in most logs.

• Cycle: 8–12 week research blocks, then 4 weeks off.

• A 12-week 1.6 mg × 2/week block uses ~8 vials (38.4 mg).

• Do not mix in the same syringe with other peptides.

Community-reported reference — not a recommendation to use.

Oxytocin AcetateNonapeptide · 5 mg vial · ~2,500 IU equivalent

5 mg vial · 1 mg/mL · SubQ or IN

RECONSTITUTION

5 mg + 5.0 mL bac water = 1 mg/mL (1,000 mcg/mL; ~500 IU/mL).

U-100: 5 units = 50 mcg (~25 IU). 10 units = 100 mcg (~50 IU).

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days. ~2 mcg ≈ 1 IU.

PROTOCOL · THIS VIAL

WORKING SUBQ · INTRANASAL

Research range · Alt. route

50–200 mcg · 10–24 IU

1× daily or as-needed · 1–2× daily

Split nostrils

DRAW TABLE · 5 mg IN 5.0 mL (1 mg/mL)

Dose · Approx IU · Units · mL · Doses / vial

50 mcg · ~25 IU · 5 · 0.05 · 100

100 mcg · ~50 IU · 10 · 0.10 · 50

200 mcg · ~100 IU · 20 · 0.20 · 25

500 mcg · ~250 IU · 50 · 0.50 · 10

Very short plasma half-life. Effects are acute per dose — this is not a weekly compound.

DURATION · ROUTE · NOTES

• Route: subcutaneous (abdomen) or intranasal. Do not treat research SubQ math as an obstetric IV protocol.

• Cycle: often 4–8 weeks on, or used as-needed rather than as a continuous daily peptide.

• One 5 mg vial at 100 mcg daily lasts ~50 days on paper; discard at 28 days after recon.

Community-reported reference — not a recommendation to use.

Melanotan IINon-selective melanocortin agonist · 10 mg vial

10 mg vial · 5 mg/mL · Load then weekly

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 2 units = 100 mcg. 5 units = 250 mcg. 10 units = 500 mcg.

Swirl, do not shake. Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

DAYS 1–14 · AFTER TAN SETS

Load / assess · Maintain

100–250 mcg · 250–500 mcg

Once daily · 1–2× weekly

Evening · Hold, do not chase

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Doses / vial

100 mcg · 2 · 0.02 · 100

250 mcg · 5 · 0.05 · 40

500 mcg · 10 · 0.10 · 20

1.0 mg · 20 · 0.20 · 10

Start at 100–250 mcg. Nausea, flushing, and spontaneous erections are the usual reasons to stay low.

DURATION · ROUTE · NOTES

• Route: subcutaneous, abdomen, evening during the load.

• Cycle: 10–14 day daily load, then 1–2× weekly maintenance. Stop the daily phase once pigmentation plateaus.

• One 10 mg vial at 250 mcg daily lasts 40 days on paper; discard at 28 days after recon.

• Community convention only. Not a licensed tanning product.

Community-reported reference — not a recommendation to use.

SemaxACTH(4–10) analog · 10 mg vial

10 mg vial · 5 mg/mL · IN or SubQ

RECONSTITUTION

Intranasal: 10 mg + 2.0 mL bacteriostatic or sterile water = 5 mg/mL.

0.10 mL (10 units) = 500 mcg. Typical spray or syringe-drop is 100–300 mcg per nostril.

Refrigerate 2–8 °C. Use within 28 days. Discard if cloudy.

PROTOCOL · THIS VIAL

DAYS 1–10 · DAYS 11–20

On · Off

300–600 mcg/day · —

1–2× daily · No compound

IN or SubQ · Then repeat

DRAW / DROP TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Amount · Volume · Route note

150 mcg · 3 units / 0.03 mL · Single IN drop

300 mcg · 6 units / 0.06 mL · Split between nostrils

600 mcg · 12 units / 0.12 mL · Daily total, split AM/midday

Do not run Semax continuously. 10 days on / 10 days off is the usual research cadence.

DURATION · ROUTE · NOTES

• Preferred route in most logs: intranasal. SubQ 150–300 mcg is the injectable alternative.

• Morning and early afternoon only — late dosing is often logged as sleep-disruptive.

• One 10 mg vial covers several 10-day on-blocks at 300–600 mcg/day.

Community-reported reference — not a recommendation to use.

SelankTuftsin analog · 10 mg vial

10 mg vial · 5 mg/mL · IN or SubQ

RECONSTITUTION

Intranasal: 10 mg + 2.0 mL bacteriostatic or sterile water = 5 mg/mL.

0.05 mL (5 units) = 250 mcg. 0.10 mL (10 units) = 500 mcg.

Refrigerate 2–8 °C. Use within 28 days.

PROTOCOL · THIS VIAL

DAYS 1–14 · DAYS 15–28

On · Off

250–500 mcg/day · —

1–2× daily · No compound

IN or SubQ · Then repeat

DRAW / DROP TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Amount · Volume · Route note

250 mcg · 5 units / 0.05 mL · Once daily IN

500 mcg · 10 units / 0.10 mL · Split AM / afternoon

14 days on / 14 days off, or 10/10, are both used. Do not run daily for months without off-days.

DURATION · ROUTE · NOTES

• Preferred route: intranasal. SubQ 250–500 mcg is the injectable alternative.

• Often logged in the same calendar as Semax but not necessarily the same days.

• One 10 mg vial covers multiple 14-day on-blocks at 250–500 mcg/day.

Community-reported reference — not a recommendation to use.

Semax + Selank10 mg + 10 mg · 20 mg combo vial

10 + 10 mg vial · Locked 1:1 · Cycled days

RECONSTITUTION

20 mg combo (10 mg Semax + 10 mg Selank) + 2.0 mL bacteriostatic or sterile water = 10 mg/mL total (5 mg/mL each).

U-100: 5 units = 250 mcg each. 6 units = 300 mcg each. 10 units = 500 mcg each.

Refrigerate 2–8 °C. Use within 28 days. Discard if cloudy.

PROTOCOL · THIS BLEND

DAYS 1–10 · DAYS 11–20

On · Off

250–300 mcg ea. · —

1–2× daily · No compound

IN preferred · Then repeat

DRAW / DROP TABLE · 20 mg COMBO IN 2.0 mL

Each peptide · Units · mL · Route note

150 mcg · 3 · 0.03 · Single IN drop

250 mcg · 5 · 0.05 · Once daily IN

300 mcg · 6 · 0.06 · Split nostrils

500 mcg · 10 · 0.10 · Daily total, split AM / midday

Locked 1:1. Separate vials are required to run Semax and Selank on different day-counts.

DURATION · ROUTE · NOTES

• Preferred route: intranasal. SubQ 150–300 mcg each is the injectable alternative.

• Morning and early afternoon only — late Semax dosing is often logged as sleep-disruptive.

• Do not run continuously. One combo vial covers several 10-day on-blocks at 250–300 mcg each.

Community-reported reference — not a recommendation to use.

5-Amino-1MQNNMT-pathway research compound · 10 mg vial

10 mg vial · 10 mg/mL · Daily

RECONSTITUTION

10 mg + 1.0 mL bac water = 10 mg/mL.

U-100: 50 units = 5 mg. 100 units = 10 mg (whole vial).

Refrigerate 2–8 °C. Use within 28 days. Confirm this is the lyophilized injectable lot, not a capsule lot.

PROTOCOL · THIS 10 mg VIAL

WEEKS 1–4 · WEEKS 5–8

Start · Working

5–10 mg · 10–20 mg

Once daily · Once daily

AM · Then 4 wks off

DRAW TABLE · 10 mg IN 1.0 mL (10 mg/mL)

Dose · Units · mL · Doses / vial · Fits this vial?

5 mg · 50 · 0.50 · 2 · Yes — start

10 mg · 100 · 1.00 · 1 · Whole vial

20 mg · 200 · 2.00 · — · Use 50 mg vial

Published human dosing for an injectable 5-Amino-1MQ standard does not exist. These are working ranges only.

DURATION · ROUTE · NOTES

• Route: subcutaneous if this is the lyophilized vial.

• Cycle: 4–8 weeks on, 4 weeks off.

• Sister card: 50 mg vial. Move up once the working dose is 10–20 mg daily.

Community-reported reference — not a recommendation to use.

5-Amino-1MQNNMT-pathway research compound · 50 mg vial

50 mg vial · 20 mg/mL · Daily

RECONSTITUTION

50 mg + 2.5 mL bac water = 20 mg/mL.

U-100: 25 units = 5 mg. 50 units = 10 mg. 100 units = 20 mg.

Refrigerate 2–8 °C. Use within 28 days. Confirm this is the lyophilized injectable lot, not a capsule lot.

PROTOCOL · THIS 50 mg VIAL

WEEKS 1–4 · WEEKS 5–8

Start · Working

5–10 mg · 10–20 mg

Once daily · Once daily

AM · Then 4 wks off

DRAW TABLE · 50 mg IN 2.5 mL (20 mg/mL)

Dose · Units · mL · Doses / vial

5 mg · 25 · 0.25 · 10

10 mg · 50 · 0.50 · 5

20 mg · 100 · 1.00 · 2.5

Same working range as the 10 mg card — this vial is the one that actually covers a 10–20 mg daily block.

DURATION · ROUTE · NOTES

• Route: subcutaneous if this is the lyophilized vial.

• Cycle: 4–8 weeks on, 4 weeks off.

• Do not combine high daily 5-Amino-1MQ with aggressive calorie restriction in the same first week.

• Sister card: 10 mg vial for the 5 mg start step.

Community-reported reference — not a recommendation to use.

Kisspeptin-10Kp-10 fragment · 10 mg vial

10 mg vial · 5 mg/mL · 2–3× weekly

RECONSTITUTION

10 mg + 2.0 mL bac water = 5 mg/mL.

U-100: 2 units = 100 mcg. 4 units = 200 mcg.

Refrigerate 2–8 °C. Use within 28 days. Small draws — use a U-100 with half-unit marks if available.

PROTOCOL · THIS VIAL

WEEKS 1–4 · WEEKS 5–8

Working · Hold or stop

100–200 mcg · 100–200 mcg

2–3× weekly · 2× weekly

AM · Then 4 wks off

DRAW TABLE · 10 mg IN 2.0 mL (5 mg/mL)

Dose · Units · mL · Doses / vial

100 mcg · 2 · 0.02 · 100

200 mcg · 4 · 0.04 · 50

Micro-draws. Diluting the 10 mg vial with 5.0 mL (2 mg/mL) makes 100 mcg = 5 units if 2-unit draws are impractical.

DURATION · ROUTE · NOTES

• Route: subcutaneous.

• Cycle: 4–8 weeks on, 4 weeks off. Do not treat as a daily peptide.

• One vial lasts many weeks at 100–200 mcg 2–3× weekly.

Community-reported reference — not a recommendation to use.

Go deeper

See the compound-by-compound evidence — human trials versus anecdotes, regulatory status and the original sources — in the Peptide Research Evidence Center, and the full blend profiles above under Community blends and stacks.